CA2491313A1 - Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use - Google Patents
Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use Download PDFInfo
- Publication number
- CA2491313A1 CA2491313A1 CA002491313A CA2491313A CA2491313A1 CA 2491313 A1 CA2491313 A1 CA 2491313A1 CA 002491313 A CA002491313 A CA 002491313A CA 2491313 A CA2491313 A CA 2491313A CA 2491313 A1 CA2491313 A1 CA 2491313A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- intraocular implant
- glyceryl
- coo
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Abstract
Solid or semi-solid intraocular implant compositions are disclosed. The compositions contain a lipophilic compound but lack a polymeric ingredient.< /SDOAB>
Claims (25)
1. An intraocular implant composition comprising a lipophilic compound having a molecular weight of 150 - 4000 and a pharmaceutically effective amount of a drug, but lacking a polymeric ingredient and an organic solvent that is miscible with or dispersible in water, wherein the composition is solid or semi-solid at temperatures <=37 °C and the lipophilic compound is of the formula wherein R1 is -H, -OH, -COOH, -C n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -COOH, -C n H2n+1-2m, -OOCC n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -C n H2m+1-2m COO(CH2CH2O)n CH2CH2OH, -OOCC n H2n+1-2m COOC n'H2n+1-2m', -COO-Na+, -COO-K+, -SO3H, -SO3-Na+, -SO3-K+, -NH2, -Cl, n, n' and n" are independently 0 - 50; and m, m' and m" are independently 0 - 10.
2. The intraocular implant composition of Claim 1 wherein the composition is solid or semi-solid at temperatures <=34 °C.
3. The intraocular implant composition of Claim 1 wherein the molecular weight of the lipophilic compound of formula (I) is <=2000.
4. The intraocular implant composition of Claim 3 wherein the molecular weight of the lipophilic compound of formula (I) is <=1000.
5. The intraocular implant composition of Claim 1 wherein the composition comprises a mixture of two or more lipophilic compounds of formula (I).
6. The intraocular implant composition of Claim 1 wherein the lipophilic compound of formula (I) has a melting point >= 34 °C.
7. The intraocular implant composition of Claim 5 wherein at least one lipophilic compound of formula (1) has a melting point < 34 °C but the mixture has a melting point >= 34 °C.
8. The intraocular implant composition of Claim 1 wherein R1 is, -C n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -COOH, -C n H2n+1-2 m, -OOCC n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -C n H2n+1-2m COO(CH2CH2O)n CH2CH2OH, or -OOCC n H2n+1-2m COOC n'H2n+1-2m';
n, n' and n" are independently 0 - 40; and m, m' and m" are independently 0 - 5.
n, n' and n" are independently 0 - 40; and m, m' and m" are independently 0 - 5.
9. The intraocular implant composition of Claim 8 wherein R1 is R2, R3 and R4 are independently -H, -OH, -COOH, -C n H2n+1-2m, or -OOCC n H2n+1-2m;
n, n' and n" are independently 0 - 30; and m, m' and m" are independently 0 - 3.
n, n' and n" are independently 0 - 30; and m, m' and m" are independently 0 - 3.
10. The intraocular implant composition of Claim 1 wherein the lipophilic compound of formula (I) is selected from the group consisting of diethylene glycol monostearate; propylene glycol monostearate; glyceryl monostearate;
glyceryl monolinoleate; glyceryl monooleate; glyceryl monopalmitate; and mixtures thereof.
glyceryl monolinoleate; glyceryl monooleate; glyceryl monopalmitate; and mixtures thereof.
11. The intraocular implant composition of Claim 1 wherein the lipophilic compound of formula (I) is selected from the group consisting of: glyceryl monolaurate; glyceryl dilaurate; glyceryl monomyristate; glyceryl dimyristate;
glyceryl monopalmitate; glyceryl dipalmitate; glyceryl monostearate; glyceryl distearate; glyceryl monooleate; glyceryl dioleate; glyceryl monolinoleate;
glyceryl dilinoleate; glyceryl monoarachidate; glyceryl diarachidate; glyceryl monobehenate; and glyceryl dibehenate.
glyceryl monopalmitate; glyceryl dipalmitate; glyceryl monostearate; glyceryl distearate; glyceryl monooleate; glyceryl dioleate; glyceryl monolinoleate;
glyceryl dilinoleate; glyceryl monoarachidate; glyceryl diarachidate; glyceryl monobehenate; and glyceryl dibehenate.
12. The intraocular implant composition of Claim 1 wherein the composition comprises at least 10 % (wt.) of the lipophilic compound of formula (I).
13. The intraocular implant composition of Claim 12 wherein the composition comprises at least 30 % (wt.) of the lipophilic compound of formula (1).
14. The intraocular implant composition of Claim 13 wherein the composition comprises at least 50 % (wt.) of the lipophilic compound of formula (I).
15. The intraocular implant composition of Claim 1 wherein the drug is selected from the group consisting of anti-glaucoma agents; anti-infective agents; non-steroidal and steroidal anti-inflammatory agents; growth factors;
immunosuppressant agents; neuroprotectant agents; angiogenesis-inhibiting agents and anti-allergy agents.
immunosuppressant agents; neuroprotectant agents; angiogenesis-inhibiting agents and anti-allergy agents.
16. The intraocular implant composition of Claim 1 wherein the composition further comprises one or more excipients selected from the group consisting of surfactants, preservatives, and stabilizers.
17. The intraocular implant composition of Claim 16 wherein the composition comprises a surfactant selected from the group consisting of tyloxapol;
polysorbate 20; polysorbate 60; and polysorbate 80.
polysorbate 20; polysorbate 60; and polysorbate 80.
18. The intraocular implant composition of Claim 16 wherein the composition comprises a preservative selected from the group consisting of quaternary ammonium preservatives.
19 19. The intraocular implant composition of Claim 16 wherein the composition comprises a stabilizer selected from the group consisting of chelating agents;
and antioxidants.
and antioxidants.
20. The intraocular implant composition of Claim 1 wherein the composition is fashioned into a cylindrical, conical and spherical shape.
21. A method of delivering an ophthalmically acceptable drug to the eye comprising the steps of (a) preparing an intraocular implant composition comprising a lipophilic compound having a molecular weight of 150 - 4000 and a pharmaceutically effective amount of a drug, but lacking a polymeric ingredient and an organic solvent that is miscible with or dispersible in water, wherein the composition is solid or semi-solid at temperatures <=34 °C and the lipophilic compound is of the formula wherein R1 is -H, -OH, -COOH, -C n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -COOH, -C n H2n+1-2m, -OOCC n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -C n H2n+1-2m COO(CH2CH2O)n CH2CH2OH, -OOCC n H2n+1-2m COOC n' H2n+1-2m', -COO- Na+, -COO- K+, -SO3H, -SO3-Na+, - SO3-K+, -NH2, -Cl, n, n' and n" are independently 0 - 50; and m, m' and m" are independently 0 - 10;
and (b) implanting the composition prepared in step (a) in the eye.
and (b) implanting the composition prepared in step (a) in the eye.
22. The method of Claim 21 wherein in step (b) the composition prepared in step (a) is implanted in a site selected from the group consisting of the conjunctiva) cul-de-sac; punctum; lacrimal canaliculus; anterior segment;
posterior segment; sub-Tenon's space; suprachoroidal space; and subconjunctival space.
posterior segment; sub-Tenon's space; suprachoroidal space; and subconjunctival space.
23. The method of Claim 21 wherein the composition is warmed to a temperature above room temperature and administered through a cannula.
24. The method of Claim 21 wherein the composition is administered as a solid or semi-solid.
25. The method of Claim 21 wherein the intraocular implant composition of step (a) is suspended in a liquid carrier and implanted in the eye in step (b) by administration through a cannula.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39584002P | 2002-07-15 | 2002-07-15 | |
US60/395,840 | 2002-07-15 | ||
PCT/US2003/020707 WO2004006890A1 (en) | 2002-07-15 | 2003-06-30 | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2491313A1 true CA2491313A1 (en) | 2004-01-22 |
CA2491313C CA2491313C (en) | 2011-05-24 |
Family
ID=30115932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2491313A Expired - Fee Related CA2491313C (en) | 2002-07-15 | 2003-06-30 | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
Country Status (18)
Country | Link |
---|---|
US (2) | US7678827B2 (en) |
EP (1) | EP1521573B1 (en) |
JP (1) | JP4463681B2 (en) |
KR (1) | KR101003518B1 (en) |
CN (1) | CN100355455C (en) |
AT (1) | ATE382330T1 (en) |
AU (1) | AU2003248777B2 (en) |
BR (1) | BR0312635A (en) |
CA (1) | CA2491313C (en) |
CY (1) | CY1107166T1 (en) |
DE (1) | DE60318446T2 (en) |
DK (1) | DK1521573T3 (en) |
ES (1) | ES2295647T3 (en) |
MX (1) | MXPA05000632A (en) |
PL (1) | PL206594B1 (en) |
PT (1) | PT1521573E (en) |
WO (1) | WO2004006890A1 (en) |
ZA (2) | ZA200410096B (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6955661B1 (en) * | 1999-01-25 | 2005-10-18 | Atrium Medical Corporation | Expandable fluoropolymer device for delivery of therapeutic agents and method of making |
US7947015B2 (en) * | 1999-01-25 | 2011-05-24 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
US20070184089A1 (en) * | 2002-07-15 | 2007-08-09 | Alcon, Inc. | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use |
DK1521573T3 (en) * | 2002-07-15 | 2008-03-25 | Alcon Inc | Non-polymeric, lipophilic, pharmaceutical implant compositions for intracellular use |
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
JP5097883B2 (en) * | 2004-09-02 | 2012-12-12 | 株式会社 神崎高級工機製作所 | Hydraulic drive vehicle |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US8962023B2 (en) | 2004-09-28 | 2015-02-24 | Atrium Medical Corporation | UV cured gel and method of making |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
ATE425740T1 (en) * | 2005-09-21 | 2009-04-15 | Univ Aston | CHRONOTHERAPEUTIC OCCULAR DELIVERY SYSTEM COMPRISING A COMBINATION OF PROSTAGLANDINS AND A BETA BLOCKER FOR THE TREATMENT OF PRIMARY GLAUCOMA |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US9173773B2 (en) * | 2006-06-21 | 2015-11-03 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for the delivery of active agents |
US20080045911A1 (en) * | 2006-06-21 | 2008-02-21 | Borgia Maureen J | Punctal plugs for the delivery of active agents |
US9474645B2 (en) * | 2006-06-21 | 2016-10-25 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for the delivery of active agents |
UY30883A1 (en) | 2007-01-31 | 2008-05-31 | Alcon Res | PUNCTURAL PLUGS AND METHODS OF RELEASE OF THERAPEUTIC AGENTS |
WO2009035562A2 (en) * | 2007-09-07 | 2009-03-19 | Qlt Plug Delivery, Inc | Drug cores for sustained release of therapeutic agents |
TWI451862B (en) * | 2007-10-09 | 2014-09-11 | Alcon Res Ltd | Thermal coefficient driven drug pellet size for ophthalmic injection |
TWI498136B (en) * | 2007-10-09 | 2015-09-01 | Alcon Res Ltd | An injection device for delivering a rate and temperature-dependent substance into the eye and method of preparing the same |
JP2010104632A (en) | 2008-10-31 | 2010-05-13 | Hoya Corp | Ophthalmic composition having gelling ability |
US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
US8632511B2 (en) * | 2009-05-06 | 2014-01-21 | Alcon Research, Ltd. | Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
EP2498783B1 (en) | 2009-11-09 | 2018-08-22 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
US8177747B2 (en) * | 2009-12-22 | 2012-05-15 | Alcon Research, Ltd. | Method and apparatus for drug delivery |
SI2515887T1 (en) * | 2009-12-22 | 2018-10-30 | Ucb Biopharma Sprl | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
WO2012009707A2 (en) | 2010-07-16 | 2012-01-19 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
DE102011016277B4 (en) * | 2011-04-06 | 2013-02-21 | Heraeus Medical Gmbh | Plastic deformable, biodegradable hemostyptic and method of molding such |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
CA2901280A1 (en) | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Sustained drug delivery implant |
WO2015046281A1 (en) * | 2013-09-26 | 2015-04-02 | 参天製薬株式会社 | Aqueous composition containing stabilized 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
WO2015184173A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
WO2017184881A1 (en) | 2016-04-20 | 2017-10-26 | Harold Alexander Heitzmann | Bioresorbable ocular drug delivery device |
CA3038115A1 (en) * | 2016-09-30 | 2018-04-05 | Mati Therapeutics Inc. | Ophthalmic drug sustained release formulation and uses thereof |
WO2018229653A1 (en) | 2017-06-13 | 2018-12-20 | Novartis Ag | Intraocular lens compositions |
RU2675691C1 (en) * | 2017-09-14 | 2018-12-21 | Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации | Method of long-term perfusion of subtenon space with medicines |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4014335A (en) | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
JPS6042766B2 (en) | 1978-12-09 | 1985-09-25 | 日本化薬株式会社 | Base |
US4797288A (en) | 1984-10-05 | 1989-01-10 | Warner-Lambert Company | Novel drug delivery system |
GB8524421D0 (en) | 1985-10-03 | 1985-11-06 | Boots Co Plc | Therapeutic agents |
US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
JP2893191B2 (en) | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | Controlled release matrix agent |
US5015474A (en) * | 1988-11-22 | 1991-05-14 | Parnell Pharmaceuticals, Inc. | Composition for imparting moisture to a substrate |
CA2045469A1 (en) * | 1989-02-17 | 1990-08-18 | Alan L. Weiner | Lipid excipient for nasal delivery and topical application |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US5660851A (en) | 1989-12-26 | 1997-08-26 | Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem | Ocular inserts |
JPH05507683A (en) | 1990-04-27 | 1993-11-04 | アラーガン、インコーポレイテッド | Polymer drug delivery system |
IE65045B1 (en) | 1990-04-28 | 1995-10-04 | Takeda Chemical Industries Ltd | Granulated preparations and method of producing the same |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
DE69231359T2 (en) | 1991-05-13 | 2001-02-08 | Boots Co Ltd | PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN SALT |
US5629019A (en) * | 1992-02-27 | 1997-05-13 | Alza Corporation | Formulations with hydrophobic permeation enhancers |
US5178635A (en) | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
WO1994005257A1 (en) | 1992-09-08 | 1994-03-17 | Allergan, Inc. | Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle |
WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
US5433951A (en) | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5773021A (en) | 1994-03-14 | 1998-06-30 | Vetoquinol S.A. | Bioadhesive ophthalmic insert |
CA2119109C (en) | 1994-03-15 | 2002-11-12 | Florian Gurtler | Bioadhesive ophthalmic insert |
JP4259610B2 (en) | 1994-04-08 | 2009-04-30 | キューエルティー・ユーエスエイ・インコーポレーテッド | Liquid delivery composition |
US6190691B1 (en) | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
AUPM897594A0 (en) | 1994-10-25 | 1994-11-17 | Daratech Pty Ltd | Controlled release container |
DE69529572T2 (en) | 1994-11-10 | 2003-06-18 | Univ Kentucky Res Foundation L | IMPLANTABLE REFILLABLE DEVICE WITH CONTROLLED RELEASE FOR ADMINISTERING MEDICINAL SUBSTANCES DIRECTLY ON AN INNER PART OF THE BODY |
US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US5718922A (en) | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
WO1997018817A1 (en) | 1995-11-20 | 1997-05-29 | Kiyoshi Kita | External preparation containing vitamin d or vitamin k |
US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
JP2001515491A (en) * | 1997-03-12 | 2001-09-18 | アボツト・ラボラトリーズ | Lipophilic binary system for administration of lipophilic compounds |
US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
JP2001513369A (en) | 1997-08-11 | 2001-09-04 | アラーガン・セイルズ・インコーポレイテッド | Sterile bioerodible implant devices and methods with improved biocompatibility |
IL121647A (en) * | 1997-08-28 | 2001-07-24 | Pharmateam Dev Ltd | Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate |
US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6099853A (en) * | 1997-09-04 | 2000-08-08 | Protein Express | Vaginal suppository vaccine for urogenital infections |
US5891476A (en) * | 1997-12-22 | 1999-04-06 | Reo; Joe P. | Tastemasked pharmaceutical system |
DE19804310A1 (en) * | 1998-02-04 | 1999-08-05 | Aventis Res & Tech Gmbh & Co | Spiro compounds and their use |
AU6608701A (en) * | 2000-06-21 | 2002-01-02 | Audit Institute For Medical Services And Quality Assurance Gmbh | Pharmaceutical preparations containing cyclosporines and neutral oils |
DE10030378A1 (en) * | 2000-06-21 | 2002-03-14 | Audit Inst For Medical Service | New pharmaceutical composition for topical application of water-insoluble and / or poorly water-soluble active ingredients |
AR038628A1 (en) | 2002-03-04 | 2005-01-19 | Novartis Ag | OPHTHALM COMPOSITION |
DK1521573T3 (en) * | 2002-07-15 | 2008-03-25 | Alcon Inc | Non-polymeric, lipophilic, pharmaceutical implant compositions for intracellular use |
US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
-
2003
- 2003-06-30 DK DK03764334T patent/DK1521573T3/en active
- 2003-06-30 AT AT03764334T patent/ATE382330T1/en active
- 2003-06-30 WO PCT/US2003/020707 patent/WO2004006890A1/en active IP Right Grant
- 2003-06-30 PT PT03764334T patent/PT1521573E/en unknown
- 2003-06-30 CA CA2491313A patent/CA2491313C/en not_active Expired - Fee Related
- 2003-06-30 ES ES03764334T patent/ES2295647T3/en not_active Expired - Lifetime
- 2003-06-30 MX MXPA05000632A patent/MXPA05000632A/en active IP Right Grant
- 2003-06-30 EP EP03764334A patent/EP1521573B1/en not_active Expired - Lifetime
- 2003-06-30 CN CNB038167913A patent/CN100355455C/en not_active Expired - Fee Related
- 2003-06-30 JP JP2004521511A patent/JP4463681B2/en not_active Expired - Fee Related
- 2003-06-30 PL PL374743A patent/PL206594B1/en not_active IP Right Cessation
- 2003-06-30 BR BR0312635-8A patent/BR0312635A/en not_active IP Right Cessation
- 2003-06-30 KR KR1020057000488A patent/KR101003518B1/en not_active IP Right Cessation
- 2003-06-30 US US10/610,435 patent/US7678827B2/en not_active Expired - Fee Related
- 2003-06-30 AU AU2003248777A patent/AU2003248777B2/en not_active Ceased
- 2003-06-30 DE DE60318446T patent/DE60318446T2/en not_active Expired - Lifetime
-
2004
- 2004-12-14 ZA ZA200410096A patent/ZA200410096B/en unknown
- 2004-12-14 ZA ZA200410095A patent/ZA200410095B/en unknown
-
2008
- 2008-01-31 CY CY20081100111T patent/CY1107166T1/en unknown
- 2008-06-03 US US12/132,003 patent/US8178576B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1521573B1 (en) | 2008-01-02 |
CY1107166T1 (en) | 2012-10-24 |
DE60318446T2 (en) | 2008-05-21 |
JP4463681B2 (en) | 2010-05-19 |
ATE382330T1 (en) | 2008-01-15 |
ZA200410095B (en) | 2006-07-26 |
CA2491313C (en) | 2011-05-24 |
DE60318446D1 (en) | 2008-02-14 |
JP2006500328A (en) | 2006-01-05 |
ES2295647T3 (en) | 2008-04-16 |
WO2004006890A1 (en) | 2004-01-22 |
CN1668277A (en) | 2005-09-14 |
US7678827B2 (en) | 2010-03-16 |
KR20050023409A (en) | 2005-03-09 |
MXPA05000632A (en) | 2005-03-31 |
PL206594B1 (en) | 2010-08-31 |
PL374743A1 (en) | 2005-10-31 |
US8178576B2 (en) | 2012-05-15 |
AU2003248777B2 (en) | 2008-02-14 |
PT1521573E (en) | 2008-02-08 |
US20040013704A1 (en) | 2004-01-22 |
EP1521573A1 (en) | 2005-04-13 |
US20080241224A1 (en) | 2008-10-02 |
BR0312635A (en) | 2005-04-19 |
AU2003248777A1 (en) | 2004-02-02 |
KR101003518B1 (en) | 2010-12-30 |
CN100355455C (en) | 2007-12-19 |
ZA200410096B (en) | 2006-07-26 |
DK1521573T3 (en) | 2008-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2491313A1 (en) | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use | |
JP2006500328A5 (en) | ||
CA2703000C (en) | Water-immiscible materials as vehicles for drug delivery | |
ES2561083T3 (en) | Intracameral implants of sustained release therapeutic agents | |
CA3014633C (en) | Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors | |
US8980839B2 (en) | Topical aqueous nanomicellar, ophthalmic solutions and uses thereof | |
US20060210604A1 (en) | Ocular delivery of polymeric delivery formulations | |
JP2019534867A (en) | Composition comprising a cannabinoid receptor binding ligand | |
WO2005099667A2 (en) | Drug delivery compositions | |
KR20080011310A (en) | Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders | |
US20090118262A1 (en) | Non-Aqueous Water-Miscible Materials as Vehicles for Drug Delivery | |
JP2022541874A (en) | Microemulsion composition | |
CA2491312A1 (en) | Bioerodible film for ophthalmic drug delivery | |
KR20080011311A (en) | Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders | |
CA2146006C (en) | Use of ergoline derivatives for the treatment of glaucoma | |
Khoobehi et al. | Clearance of fluorescein incorporated into microspheres from the cornea and aqueous after subconjunctival injection | |
PATEL et al. | A COMPREHENSIVE REVIEW ON PRONIOSOMES: A NEW CONCEPT IN OCULAR DRUG DELIVERY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20180703 |